Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Novo Nordisk discontinues AERx development

Novo Nordisk discontinues AERx development

15th January 2008

The development of an inhaled insulin system by Novo Nordisk is to cease following a review of the company’s operating profits.

Based on an evaluation of prospects for inhaled insulin products and the commercial viability of AERx, Novo Nordisk has opted to “refocus” its efforts in this area, it announced yesterday.

Used in connection with meals, the AERx system delivers “fast-acting” insulin and is currently part of a phase III clinical trial.

However, the firm has decided that this type of insulin administration system may not provide significant benefits for users when compared to a pen device equivalent.

“In general, people with type 2 diabetes start insulin therapy with long-acting or premixed insulin,” explained Lars Rebien Sorensen, president and chief executive officer of Novo Nordisk.

“Experience shows that they want very simple, very convenient devices for administering their insulin. This requires a completely new approach to inhalation of insulin.”

Those participating in the trial will now be switched to a recommended equivalent, the company added.

Meanwhile, the inhaled insulin drug Exubera will now no longer be manufactured by Pfizer after the company returned its worldwide licence for production and retail of the treatment, the Telegraph reports today.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.